Gilead Sciences, Inc. (NASDAQ:GILD)

CAPS Rating: 5 out of 5

A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

Results 1 - 20 of 355 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar Haiphen (< 20) Submitted: 11/23/2014 7:58:59 AM : Outperform Start Price: $101.11 GILD Score: -0.89

Looks like great value for such a high-growth stock. Low PE and Low PEG.

Recs

0
Member Avatar TMFInnovator (40.72) Submitted: 11/23/2014 1:02:51 AM : Outperform Start Price: $101.11 GILD Score: -0.89

A powerhouse with Sovaldi and still an extremely strong pipeline. Think that Gilead continues to outperform.

Recs

0
Member Avatar littleoldmedng (< 20) Submitted: 11/21/2014 10:54:52 AM : Outperform Start Price: $100.64 GILD Score: -0.52

Good Value and bound to rebound. Time to get in

Recs

0
Member Avatar cmrk3 (30.43) Submitted: 11/19/2014 10:14:13 AM : Outperform Start Price: $39.82 GILD Score: +114.02

Saving lives through selling expensive medicine.

Recs

0
Member Avatar TMFTiptree (28.12) Submitted: 11/14/2014 2:14:41 PM : Outperform Start Price: $101.60 GILD Score: -2.97

Innovative company with a strong pipeline of drugs, plus a blockbuster gaining momentum.

Recs

0
Member Avatar purplehayes4 (54.92) Submitted: 11/8/2014 7:09:24 AM : Outperform Start Price: $109.07 GILD Score: -9.99

R&D seems to be their strong suit. Will be a leader for many years to come.

Recs

0
Member Avatar jdbow (52.56) Submitted: 11/7/2014 10:47:20 AM : Outperform Start Price: $98.43 GILD Score: -8.00

needed a drug company in my portfolio and this look like a good one

Recs

0
Member Avatar natureperfect7 (< 20) Submitted: 10/31/2014 1:19:17 AM : Outperform Start Price: $109.91 GILD Score: -11.63

The produce is much needed and is successful.

Recs

0
Member Avatar JeffRossMD (< 20) Submitted: 10/30/2014 12:44:05 PM : Outperform Start Price: $113.70 GILD Score: -16.02

The biotech space is just heating up as new technologies are revolutionizing cancer and chronic disease processes.

Recs

0
Member Avatar bartlettmi (69.93) Submitted: 10/29/2014 12:57:20 PM : Outperform Start Price: $109.65 GILD Score: -13.21

Not just a Hep-C company... This stock's run is not over.

Recs

0
Member Avatar lernout1973 (39.10) Submitted: 10/29/2014 6:01:29 AM : Outperform Start Price: $109.85 GILD Score: -13.12

strong growth, generates massive cash, good chance/risk ratio

Recs

0
Member Avatar rpd5 (< 20) Submitted: 10/28/2014 9:15:41 PM : Outperform Start Price: $99.67 GILD Score: +0.57

Solvadi continues to sell well

Recs

0
Member Avatar Deepvaluestocks (< 20) Submitted: 10/27/2014 4:40:05 PM : Outperform Start Price: $113.25 GILD Score: -16.78

GILD had the best in class treatment for Hepatitis C in Harvoni and trades at a forward PE under 13, which is very low considering the potential growth.

Recs

0
Member Avatar russfischer1013 (94.53) Submitted: 10/26/2014 11:58:13 PM : Outperform Start Price: $110.77 GILD Score: -15.38

valuation = $180

Recs

0
Member Avatar dplan4money (70.59) Submitted: 10/21/2014 9:58:40 PM : Outperform Start Price: $106.51 GILD Score: -12.48

HepC drug = money

Recs

0
Member Avatar gunngun (< 20) Submitted: 10/21/2014 6:02:05 AM : Underperform Start Price: $104.05 GILD Score: +11.78

It's gone up too much too fast and is due for a sizable correction.

Recs

0
Member Avatar Tophinater (33.86) Submitted: 10/20/2014 3:32:42 PM : Outperform Start Price: $102.07 GILD Score: -10.82

><)));'>

Recs

0
Member Avatar roger55 (< 20) Submitted: 10/19/2014 3:25:46 AM : Outperform Start Price: $101.15 GILD Score: -11.06

have new drug approved by fda

Recs

0
Member Avatar Sceaj (< 20) Submitted: 10/13/2014 10:15:07 AM : Outperform Start Price: $101.92 GILD Score: -10.95

Hep "C" drug - approved for Medicaid patients. That's huge.

Recs

0
Member Avatar PLocklar (24.83) Submitted: 10/12/2014 5:19:45 PM : Outperform Start Price: $104.49 GILD Score: -12.88

outperform

Featured Broker Partners


Advertisement